Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Amylin (AMLN) is looking to sell itself, according to sources, and has hired advisers to help...

  • Monday, April 23, 2012, 2:58 AM ET
    Amylin (AMLN) is looking to sell itself, according to sources, and has hired advisers to help solicit possible offers. Several companies, possibly including Sanofi (SNY), are reportedly considering a bid to gain access to Amylin's diabetes portfolio.
Track new comments on this story

This news story has 1 comment:

  •  
    Bydureon is a mega block buster not only is it capturing all the glp-1 market it is also pulling form the insulin market not ot mention the off label use of weight loss - and when it moves out to one mos injections - well it will be in huge demand ! . Icahn is absolutely wrong on a selling price of $22 - I'd look at more like $38
    23 Apr 2012, 09:57 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »